The webinar “THE ART OF DXA ANALYSIS IN RESEARCH” has already taken place. However, for those interested in learning about Image Analysis Group’s (IAG) capabilities in DXA or watching the recording, you can access the information by contacting IAG directly or watching it here: https://www.ia-grp.com/trial_solutions/iag-provide-a-full-package-solution-for-dxa-studies/
This webinar focused on the significance of Dual-Energy X-ray Absorptiometry (DXA or DEXA) in clinical trials, particularly for studies involving bone health, osteoporosis, obesity, and related conditions. DXA is a valuable tool for accurately measuring bone mineral density and body composition, providing crucial quantitative data for assessing the efficacy of interventions and treatments.
The expert panel included:
-
Michael Clark: A Senior Clinical Director with extensive experience in strategic planning and execution of clinical programs.
-
Prof. Mikael Boesen: IAG’s Therapeutic Area Lead for Rheumatic Diseases and Auto-Immunity, with 20 years of international experience in clinical research on inflammatory and degenerative joint diseases.
-
Cristiano Costa: An expert with over a decade of experience in cross-sectional diagnostic imaging and healthcare management.
The discussion was moderated by Julia O’Lynn, who has 20+ years of expertise in targeted drug development and advanced radiologic imaging.
For those planning clinical studies or developing new treatments focusing on bone health, osteoporosis, obesity, and related conditions, incorporating DXA could be beneficial. DXA is recognized as a safe and cost-effective method for bone density measurement, both in assessing fracture risk and monitoring response to therapy.
To access the webinar recording or learn more about IAG’s capabilities in DXA analysis for research, please contact Image Analysis Group (IAG) directly through their official channels.